OTCMKTS:IGXTIntelGenx Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.21 +0.01 (+4.89 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$0.20Now: $0.21▼$0.2250-Day Range$0.16MA: $0.19▼$0.2352-Week Range$0.12Now: $0.21▼$0.70Volume452,808 shsAverage Volume263,045 shsMarket Capitalization$23.66 millionP/E RatioN/ADividend YieldN/ABeta2.25 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingIntelGenx Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.20, IntelGenx Technologies has a potential upside of 459.2% from its current price of $0.21.Amount of Analyst CoverageIntelGenx Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesIntelGenx Technologies has received 169 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntelGenx Technologies has received 174 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntelGenx Technologies has received 50.73% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote “Outperform” if you believe IGXT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IGXT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntelGenx Technologies does not currently pay a dividend.Dividend GrowthIntelGenx Technologies does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IntelGenx Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.19% of the stock of IntelGenx Technologies is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IntelGenx Technologies are expected to grow in the coming year, from ($0.06) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IntelGenx Technologies is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IntelGenx Technologies is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IGXT Previous Symbol CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone514-331-7440Debt Debt-to-Equity Ratio0.61 Current Ratio0.73 Quick Ratio0.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$740,000.00 Price / Sales31.98 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.11) Net Income$-10,660,000.00 Net Margins-1,994.13% Return on Equity-380.66% Return on Assets-80.06%Miscellaneous Employees38 Outstanding Shares110,260,000Market Cap$23.66 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable OTC:IGXT Rates by TradingView Receive IGXT News and Ratings via Email Sign-up to receive the latest news and ratings for IGXT and its competitors with MarketBeat's FREE daily newsletter. IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions How has IntelGenx Technologies' stock been impacted by COVID-19 (Coronavirus)? IntelGenx Technologies' stock was trading at $0.3950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IGXT shares have decreased by 45.7% and is now trading at $0.2146. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IntelGenx Technologies? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IntelGenx Technologies. When is IntelGenx Technologies' next earnings date? IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IntelGenx Technologies. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its earnings results on Thursday, March, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The company earned $0.07 million during the quarter, compared to the consensus estimate of $0.06 million. IntelGenx Technologies had a negative return on equity of 380.66% and a negative net margin of 1,994.13%. View IntelGenx Technologies' earnings history. What price target have analysts set for IGXT? 3 brokers have issued 12-month target prices for IntelGenx Technologies' stock. Their forecasts range from $0.50 to $1.60. On average, they expect IntelGenx Technologies' share price to reach $1.20 in the next year. This suggests a possible upside of 459.2% from the stock's current price. View analysts' price targets for IntelGenx Technologies. Has IntelGenx Technologies been receiving favorable news coverage? Media headlines about IGXT stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IntelGenx Technologies earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutIntelGenx Technologies. Who are some of IntelGenx Technologies' key competitors? Some companies that are related to IntelGenx Technologies include CV Sciences (CVSI), Aptorum Group (APM), Catalyst Biosciences (CBIO), Bellerophon Therapeutics (BLPH), TFF Pharmaceuticals (TFFP), CannTrust (CTST), Genprex (GNPX), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN), Proteostasis Therapeutics (PTI), ContraFect (CFRX), Milestone Pharmaceuticals (MIST), Monopar Therapeutics (MNPR) and Adamas Pharmaceuticals (ADMS). View all competitors. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), New Residential Investment (NRZ), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI), Energy XXI Gulf Coast (EGC) and SandRidge Energy (SD). Who are IntelGenx Technologies' key executives? IntelGenx Technologies' management team includes the following people: Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 72)Mr. Andre Godin C.A., CPA, CPA, CA, Exec. VP & CFO (Age 55)Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65) What is IntelGenx Technologies' stock symbol? IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT." How do I buy shares of IntelGenx Technologies? Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IntelGenx Technologies' stock price today? One share of IGXT stock can currently be purchased for approximately $0.21. How big of a company is IntelGenx Technologies? IntelGenx Technologies has a market capitalization of $23.66 million and generates $740,000.00 in revenue each year. The company earns $-10,660,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. IntelGenx Technologies employs 38 workers across the globe. What is IntelGenx Technologies' official website? The official website for IntelGenx Technologies is www.intelgenx.com. How can I contact IntelGenx Technologies? IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
